Genrix Bio
68844323.080.52% ( +0.12 )
Genrix Bio (688443)
Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in Ch...
- Open
- 23.13
- High
- 23.35
- Low
- 22.68
- Prev. Close
- 22.96
- Volume
- 31.56K
- Turnover
- 72.76M
- Avg Price
- 23.05
- Bid/Ask Ratio
- --
- Amplitude
- 2.92%
- 52wk High
- 37.88
- Volume Ratio
- 0.59
- Turnover Ratio
- 2.20%
Genrix Bio Analyst Rating
View MoreForecast & Rating
May 7, 2026Price forecast
¥40.0073.31%
Forecast & RatingStrong buy
2analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jun 22 at 04:31 AM
China Medical System says China approves rabies antibody drug Silevimig Injection
- Wallstreetcn · Jan 8 at 11:26 PM
The A-share innovative drug sector surged in the afternoon, with WECOME rising over 15%, Frontier Biotechnologies and SHANGHAI YIZHONG rising over 10%, and JLPC, Hongbo Pharmaceutical, Genrix Bio, and Chengda Pharmaceutical following suit
- Zhitong · Sep 22, 2025 at 06:42 AM
Genrix Bio signed a commercialization cooperation agreement for Weikang Duta monoclonal antibody injection and Sileweimi monoclonal antibody injection
- Zhitong · Sep 17, 2025 at 03:48 AM
Genrix Bio's clinical trial application for the research product GR2301 injection has been approved
- Zhitong · Sep 11, 2025 at 04:08 AM
Genrix Bio: The new drug application for Talikizumab injection has been accepted
- Zhitong · Sep 10, 2025 at 04:53 AM
Genrix Bio: GR1803 injection system for systemic lupus erythematosus indication approved for clinical trials
